Health care developer Admedus Limited
(ASX:AHZ) has expanded its CardioCel portfolio with a new bio-scaffold option in its product line.
The Brisbane based firm says the addition of a 2x2cm CardioCel product was developed after feedback from surgeons showed strong potential demand.
CEO Lee Rodne says the release is part of a continuing strategy to provide a complete range of products for all cardiovascular repairs and reconstructions.
The company’s CardioCel bio-scaffold materials are created with DNA and RNA being removed from animal tissue to create a collagen matrix used for treatment and repair.
Admedus reported a net loss of $26.8 million in the 2015 financial year.
